Epilepsy (treatment Refractory)PREDICT-PFONCT06863350
Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale（PREDICT-PFO Trial）
A study testing patent foramen ovale closure in people with Epilepsy (treatment Refractory), run by Sichuan University at 1 site in China.
Trial summary
Patent foramen ovale (PFO) is the most common cause of right-to-left shunt (RLS) in the adult heart, with a prevalence of approximately 25% in the general population. Extensive research has demonstrated an association between PFO and neurological conditions such as cryptogenic stroke, migraine, and sleep apnea… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Epilepsy (treatment Refractory)
- What is being tested?
- patent foramen ovale closure
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteChina
- Study dates
- 28 Feb 2025to 1 Jun 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age between 18 and 60 years, with no gender restrictions;
- Diagnosis of epilepsy in accordance with the International League Against Epilepsy (ILAE) criteria (2014 edition);
- Drug-resistant epilepsy, defined as failure to achieve sustained seizure freedom despite appropriate selection and tolerability of at least two antiseizure medications (monotherapy or combination therapy) for a minimum of six months;
- Diagnosis of patent foramen ovale (PFO) meeting the criteria established by the American Society of Echocardiography (ASE) and the Society for Cardiovascular Angiography and Interventions (SCAI) (2015 edition), with right-to-left shunting (RLS) of grade II or higher upon Valsalva maneuver, as assessed by contrast-enhanced echocardiography;
- Stable antiseizure medication regimen for at least four weeks prior to screening, with willingness to maintain a stable regimen throughout the study period;
- At least one documented seizure episode during a six-week screening period (with a minimum of four weeks of effective seizure diary recordings) and a retrospective self-reported history of at least 12 seizures in the year preceding screening;
- Ability to independently or with caregiver assistance complete a seizure diary and comply with clinical data collection and required medical examinations;
- Willingness to undergo the investigational treatment and voluntary provision of written informed consent.
Who cannot join
- Patients diagnosed with epilepsy of a known etiology, including infectious, metabolic, immune, genetic, or structural causes;
- History of stroke or psychogenic nonepileptic seizures (PNES);
- History of epilepsy surgery or implantable neurostimulation therapy, or planned epilepsy surgery, neurostimulation therapy, ketogenic diet therapy, or other antiseizure interventions during the study period;
- Presence of structural cardiac abnormalities other than patent foramen ovale (PFO), such as moderate or severe valvular regurgitation or pulmonary hypertension;
- Presence of severe central nervous system (CNS) diseases, including acute cerebrovascular disease, intracranial tumors, intracranial infections, or progressive CNS disorders;
- Evidence of vascular puncture site infection or difficulty with puncture as assessed by transesophageal echocardiography combined with contrast-enhanced right heart echocardiography;
Show all 13Show fewer
- Documented contraindications to antiplatelet therapy;
- Presence of severe psychiatric disorders, such as schizophrenia, bipolar disorder, or severe depression or anxiety;
- History of alcohol or other substance abuse;
- Severe dysfunction of vital organs (heart, lungs, liver, kidneys) deemed by the investigator to pose a risk to the participant or impair the participant's ability to complete the study;
- Pregnant or breastfeeding women, or women planning to conceive during the study period;
- Participation in another interventional clinical trial within three months prior to signing the informed consent form, current participation in another interventional trial, or plans to participate in another interventional trial during the study period; inability to comply with follow-up due to travel or relocation;
- Any other condition that the investigator determines makes the patient unsuitable for participation in this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Westchina Hospital
Chengdu, Sichuan, 610041
+8619980483686
About this study
Official title: Efficacy and Safety of Percutaneous Foramen Ovale Closure in Adult Patients with Drug-resistant Epilepsy and Patent Foramen Ovale: a Randomized Controlled Trial
Patent foramen ovale (PFO) is the most common cause of right-to-left shunt (RLS) in the adult heart, with a prevalence of approximately 25% in the general population. Extensive research has demonstrated an association between PFO and neurological conditions such as cryptogenic stroke, migraine, and sleep apnea syndrome, and it is even considered a potential root cause of these disorders. However, the mechanisms by which PFO contributes to neurological diseases remain unclear. In our preliminary clinical work, we have observed a strong correlation between PFO and epilepsy, and PFO closure has shown some efficacy in reducing seizure frequency. The aim of this study is to further investigate the efficacy and safety of PFO closure in patients with drug-resistant epilepsy.
- Conditions
- Epilepsy (treatment Refractory)
- Being tested
- patent foramen ovale closure
- Keywords
- patent foramen ovale, epielpsy
- Medical subject headings
- Epilepsy, Foramen Ovale, Patent
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
patent foramen ovale closureDevice
patent foramen ovale closure
| Study group | Role | What they receive |
|---|---|---|
| Operation group | Experimental | patent foramen ovale closure Receives: Device: patent foramen ovale closure |
| control group | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage decrease in seizure frequency compared to baseline period
Percentage decrease in seizure frequency compared to baseline period
Measured: Week 48
Secondary outcomes (6)
Percentage decrease in mean duration of seizures from baseline period
Percentage decrease in mean duration of seizures from baseline period
Measured: Week 48
Percentage of decrease from baseline in Epilepsy Severity
Percentage of decrease from baseline in Epilepsy Severity Scale score (NHS3)
Measured: Week 48
Percentage improvement from baseline in Quality of Life for Patients with Epilepsy
Percentage improvement from baseline in Quality of Life Rating Scale for Patients with Epilepsy (QOLIE-31)
Measured: Week 48
The maximum number of observation days without sustained epileptic seizures during the follow-up observation period
The maximum number of observation days without sustained epileptic seizures during the follow-up observation period
Measured: Up to 48 weeks
The proportion of subjects whose seizure frequency decreased by more than 50% compared to the baseline period
The proportion of subjects whose seizure frequency decreased by more than 50% compared to the baseline period
Measured: Week 48
The proportion of subjects whose average duration of epileptic seizures decreased by more than 50% compared to the baseline period
The proportion of subjects whose average duration of epileptic seizures decreased by more than 50% compared to the baseline period
Measured: Week 48
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2025
- Study start28 Feb 2025 (estimated)
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Epilepsy (treatment Refractory)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sichuan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bo Zhang, Sichuan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06863350
- Sponsor's protocol ID
- HX20242572
- Other IDs
- ZYYC23011
- Acronym
- PREDICT-PFO
- Status last verified
- Mar 2025
- First submitted
- 25 Feb 2025
- Last updated
- 11 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No